Seer Q4 Earnings Call Highlights

Core Insights - Seer has demonstrated significant platform adoption through large-scale studies, including a 20,000-sample study with Korea University and a 10,000-sample project with Discovery Life Sciences, which traditional methods could not feasibly conduct [1] - Despite a challenging funding environment, Seer reported a 67% increase in installed instruments and a 69% year-over-year growth in consumable kit volume, with total revenue excluding related-party revenue growing by 33% in 2025 [2] - The company faced project delays due to NIH funding issues, which impacted customer purchasing decisions and led to results falling short of expectations [3] Financial Performance - Seer reported Q4 2025 revenue of $4.2 million and full-year revenue of $16.6 million, reflecting a 17% year-over-year growth, but cited budget pressures and NIH funding uncertainty as challenges [4] - The gross margin for Q4 was approximately 52%, with operating expenses down 23% year-over-year, resulting in a narrowed net loss of $16 million for the quarter [12][13] - For the full year, Seer ended with about $241 million in cash and investments, with a free cash flow loss of $45.6 million, an improvement from the previous year [14] Product Development and Roadmap - Seer launched its third-generation assay, Proteograph ONE, and its second-generation automation instrument, SP200, which can now process over 1,000 samples per week [7] - The company plans to release the fourth generation of its Proteograph Analysis Suite (PAS) in late 2026, incorporating AI capabilities for enhanced data interaction [7][8] - Seer is developing an end-to-end sample-to-data proteomic solution aimed at high-throughput biomarker discovery, with data expected to be shared in 2026 [9] Commercial Strategy - Approximately 60% of instruments installed in 2025 were through the Strategic Instrument Placement program, which helps customers with capital constraints [10] - Seer has expanded its partnership with Thermo Fisher Scientific to co-market the Proteograph product suite, targeting both individual accounts and large studies [11] - The company is also focusing on expanding into translational markets with plans to commercialize a proteoform profiling assay kit in 2027 [8] Future Guidance - For 2026, Seer projects revenue between $16 million and $18 million, indicating a modest growth outlook amid ongoing funding pressures [17] - The guidance does not account for potential contributions from additional population-scale studies that may be announced in 2026, which could provide upside [18] - Management views the guidance as cautious due to the current funding landscape and the challenges in shifting customer approaches to unbiased proteomics workflows [19]